

1 **Covid-19 Vaccination in Pregnancy: A Systematic Review**

2 Nando Reza Pratama<sup>1</sup>, Ifan Ali Wafa<sup>1</sup>, David Setyo Budi<sup>1</sup>, Manesha Putra<sup>2</sup>, Manggala Pasca  
3 Wardhana<sup>3,4</sup> Citrawati Dyah Kencono Wungu<sup>5,6,\*</sup>

4  
5 <sup>1</sup>Faculty of Medicine, Universitas Airlangga, Indonesia

6 <sup>2</sup>Department of Obstetrics and Gynecology, University of Colorado Anschutz School of  
7 Medicine, Aurora, United States

8 <sup>3</sup>Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga.  
9 Indonesia

10 <sup>4</sup>Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

11 <sup>5</sup>Department of Physiology and Medical Biochemistry, Faculty of Medicine, Universitas  
12 Airlangga, Indonesia

13 <sup>6</sup>Institute of Tropical Disease, Universitas Airlangga, Indonesia

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29 **Correspondence:**

30 Citrawati Dyah Kencono Wungu, MD., PhD.

31 Department of Physiology and Medical Biochemistry, Airlangga University

32 Jalan Mayjen Prof. Dr. Moestopo No.47, Surabaya, Indonesia

33 Email: [citrawati.dyah@fk.unair.ac.id](mailto:citrawati.dyah@fk.unair.ac.id)

34 **Abstract**

35 **Objective:** Pregnancy is a risk factor for severe Covid-19. Looking for safe vaccines that  
36 evoke protective maternal and fetal antibody response is important.

37 **Methods:** We searched from registries (ClinicalTrials.gov, the WHO Clinical Trial  
38 Registry, and the EU Clinical Trial Registry) and databases (MEDLINE,  
39 ScienceDirect, Cochrane Library, Proquest, and Springer) up until June 20,  
40 2021. Articles were selected based on inclusion and exclusion criteria after  
41 duplicates were removed. Infection rate, maternal antibody response, placental  
42 antibody transfer, and adverse events were described. This systematic review  
43 was performed with quality assessment and semi-quantitative synthesis  
44 according to PRISMA guidelines.

45 **Results:** Twelve observational studies with a total of 40.509 pregnant women included.  
46 The mRNA based vaccines (Pfizer-BioNTech and Moderna) can prevent  
47 future SARS-CoV-2 infections ( $p=0.0004$ ). Both vaccines did not affect  
48 pregnancy, delivery, and neonatal outcomes. The most commonly encountered  
49 adverse reactions are injection-site pain, fatigue, and headache but only  
50 transient. Antibody responses were rapid after the prime dose of vaccines.  
51 After booster, antibody responses were higher and associated with better  
52 placental antibody transfer. Longer intervals between first vaccination dose  
53 and delivery were also associated with higher antibody fetal IgG and better  
54 antibody transfer ratio.

55 **Conclusions:** The Pfizer-BioNTech and Moderna vaccines are efficacious for preventing  
56 future SARS-CoV-2 infections. These vaccines can be considered as a safe  
57 option for pregnancy and their fetus. Two doses of vaccines were  
58 recommended for more robust maternal and fetal antibody responses. Longer  
59 latency was associated with higher fetal antibody responses.

60 **Keywords:** Covid-19; Pregnancy; Vaccine; Antibody; Neonate

61 **Systematic Review Registration:** PROSPERO (CRD42021261684)

62

63

64

65

## 66 INTRODUCTION

67 The impact of coronavirus disease 2019 (Covid-19) on pregnancy remains unclear  
68 due to insufficient information, while most available studies have evaluated the impact of the  
69 disease only in the general population. The risk of severe Covid-19 in pregnancy appears to  
70 be no greater than for the general population; pregnant women are at a higher risk for  
71 acquiring viral respiratory infections and severe pneumonia due to the unique physiological  
72 changes in their immune and cardiopulmonary systems.<sup>1,2</sup> Although most pregnant women  
73 had mild to moderate symptoms only, SARS-CoV-2 infection is found more severe in  
74 pregnant women than their nonpregnant counterparts, with an increased risk of hospital  
75 admission, intensive care unit stay, and death.<sup>3</sup>

76 Despite their higher risk of SARS-CoV-2 infection, pregnant and lactating women  
77 were not included in any initial Covid-19 vaccine trials, resulting in data scarcity to guide  
78 vaccine decision making in these populations.<sup>4</sup> A prior study revealed that most pregnant  
79 women with Covid-19 admitted to the hospital were asymptomatic, which allows these  
80 undetected patients to transmit the virus to others.<sup>5,6</sup> This finding shows that efforts to prevent  
81 SARS-CoV-2 infection, one of them by vaccination, are critical for investigation on this  
82 population.

83 To facilitate comprehending the Covid-19 vaccine in pregnancy, we performed a  
84 systematic review to critically evaluate and summarize the latest evidence of Covid-19  
85 vaccination regarding the efficacy, immunogenicity, and safety profile in the pregnant  
86 population.

## 87 METHODS

88 This systematic review adhered to PRISMA (Preferred Reporting Items for Systematic  
89 Review and Meta-Analysis) 2020 guidelines<sup>7</sup> and has been previously registered in the  
90 PROSPERO database (CRD42021261684).

### 91 Eligibility criteria

92 We accepted any study (retrospective, prospective, cohort, randomized controlled trials  
93 (RCT), case series, case control, cross-sectional, crossover) to be included in the review. The  
94 authors screened the title and abstract of independently for eligible studies based on the  
95 following criteria: (1) pregnant women; (2) adult ( $\geq 18$  years) female study population; (3) the

96 study involved Covid-19 vaccine of interest; (4) the study compared the intervention group  
97 with control (non-pregnant women, unvaccinated, or none); (5) eligible studies should have  
98 reported at least one of our outcomes of interest; (6) English language. Our primary outcomes  
99 included infection rate, maternal titer antibody, local and systemic adverse events. Our  
100 secondary outcomes included neonatal outcome, cord blood titer antibody, and placental  
101 transfer ratio. We excluded review articles, irrelevant, non-human studies, and duplications.

## 102 **Search strategy and selection of studies**

103 The authors comprehensively conducted keyword searching of articles published in trial  
104 registries (ClinicalTrials.gov, the WHO Clinical Trial Registry, and the EU Clinical Trial  
105 Registry) and databases (MEDLINE, ScienceDirect, Cochrane Library, Proquest, and  
106 Springer) up until June 20, 2021. Our research is limited to studies involving humans with no  
107 language restrictions. Manual search, including in BioRxiv and MedRxiv, and the  
108 bibliographical search were also conducted to obtain additional evidence. The following  
109 keywords were used: “((SARS-CoV-2) OR (COVID-19)) AND ((pregnancy) OR (pregnant))  
110 AND ((vaccine) OR (vaccination))”. The search strategies are available in *Supplementary*  
111 *Materials*. We exported all studies retrieved from the electronic searches into Mendeley  
112 reference manager for removing duplication and screening. The two review authors (NRP  
113 and IAW) independently screened the title and abstract of the articles to identify potentially  
114 eligible studies and subsequently screened the full texts independently. Any disagreements  
115 between the two review authors were resolved by discussion until reaching consensus.  
116 Excluded studies were described in the PRISMA flow diagram alongside their reasons for  
117 exclusion (**Figure 1**).

## 118 **Data extraction**

119 The review authors (NRP, IAW, and DSB) independently extracted relevant data using  
120 structured and standardized form from each selected study. The following information was  
121 extracted: first author’s name and publication year, study design, country, sample size,  
122 gestational age at first vaccine, sample size, age, sample collection, vaccine type, and  
123 outcomes (infection rate, maternal titer antibody, cord blood titer antibody, placental transfer  
124 ratio and local and systemic adverse events). Any disagreements between the review authors  
125 were consulted with the expert and resolved by discussion until reaching consensus.

## 126 **Quality assessment**

127 Two review authors (IAW and DSB) independently assessed the risk of bias from each  
128 included studies using Newcastle-Ottawa Scale (NOS) assessment tool for cohort studies and  
129 Joanna Briggs Institute (JBI) critical appraisal checklist for case report, case series, and cross-  
130 sectional studies.<sup>8,9</sup> Newcastle-Ottawa Scale contains eight items within three domains,  
131 including patient selection, comparability, and outcomes. A study with scores 7-9, 4-6, and 0-  
132 3 were considered to be high, moderate, and low-quality, respectively. Any discrepancies  
133 were resolved by discussion until reaching consensus.

### 134 **Statistical analysis**

135 Due to important differences in comparison of each study and various outcome measures, we  
136 could not generate meta-analyses of the included studies but rather we performed narratively  
137 synthesized the evidence using Synthesis Without Meta-analysis (SWiM) reporting guideline  
138 (intended to complement the PRISMA guidelines in these cases).

## 139 **RESULTS**

### 140 **Study selection**

141 The search strategy yielded 4112 and 199 records, respectively, from database searching and  
142 additional searching, in medRxiv, bioRxiv, and clinicaltrial.gov. After screening the titles and  
143 abstracts, 47 potentially eligible articles were reviewed. After the full-text assessment, twelve  
144 studies were included in this systematic review. The process of study selection in this review  
145 is described in the PRISMA flow diagram (**Figure 1**), along with the reason for exclusion.

### 146 **Quality assessment**


147 Eight cohort studies were assessed using the NOS assessment tool and considered as high  
148 quality since all of the studies scored 7-9 (see *Table S1 in Supplementary Materials*). The  
149 quality assessment of case report, case series, and cross-sectional studies using the JBI  
150 critical appraisal checklist was summarized in Supplementary Materials (**Table S2 – S4**).

### 151 **Study characteristics**

152 There are twelve observational studies with a total of 40,509 pregnant women who received  
153 Covid-19 vaccines included in this systematic review. Among these studies, ten studies (six  
154 cohort, one cross-sectional, one case series, and two case report) were conducted in the  
155 United States of America (USA) while other two cohort studies were carried out in Israel in  
156 2021. The maternal age ranged from 16 to 54 years. All pregnant women reported receiving  
157 mRNA vaccine, either Pfizer–BioNTech or Moderna vaccine, except for four pregnant

158 women who received unknown types of vaccine.<sup>18</sup> Some studies compared vaccinated  
159 pregnant women with unvaccinated pregnant women, either naturally infected or not infected,  
160 or vaccinated non-pregnant women. The efficacy outcome was described as infection rate,  
161 while immunogenicity was described as maternal antibody response, fetal antibody response,  
162 and transplacental antibody transfer. Safety outcome was described as the adverse events,  
163 maternal outcomes, and neonatal outcomes. Adverse events were divided into local and  
164 systemic, local adverse events include injection-site pain and soreness, while systemic  
165 adverse events include fatigue, headache, myalgia, chills, fever and nausea.

166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194



**Figure 1** PRISMA flow diagram of study selection process<sup>7</sup>

195 **Table 1A.** Characteristics of the included studies

Reference	Study design	Country	Gestational age at first vaccine or 1st vaccine-to-delivery interval dose	Sample size		Age, y Mean ± SD or Median (IQR)		Sample collection	Vaccine type	Outcomes
				Pregnant (N)	Not Pregnant (N)	Pregnant (N)	Not Pregnant (N)			
Shimabukuro et al., 2021 <sup>10</sup>	Cohort	United States	NR	Vaccinated 39,870	0	Vaccinated 33 (16-54)	NR	Data from “v-safe and VAERS.	Pfizer–BioNTech and Moderna.	Infection rate, local adverse events, systemic adverse events, pregnancy loss, and neonatal outcomes.
Gray et al., 2021 <sup>11</sup>	Cohort	United States	Gestational age at first vaccine (Mean) 23.2 weeks	Vaccinated 84	Non-pregnant, received vaccine: 16	Vaccinated 34.1±3.3	Vaccinated 38.4±8.3	Antibodies in umbilical cord blood, maternal sera, and breastmilk were quantified using ELISA. Adverse events were assessed using questionnaire.	Pfizer–BioNTech and Moderna.	Maternal antibody titer, local adverse events, systemic adverse events, adverse pregnancy outcome, and composite infant morbidity.
Collier et al., 2021 <sup>12</sup>	Cohort	United States	Gestational age at first vaccine dose (N (%)) <14 week: 5 (17%) 14-28 week: 15 (50%) ≥28 week: 10 (33%)	Vaccinated 30 Infected, not vaccinated 22	Neither pregnant nor lactating, received vaccine: 63	Vaccinated 35 (32-36) Not vaccinated: 31 (28-36)	Vaccinated: 30 (25-35) Not vaccinated: 34 (33-38)	SARS-CoV-2 RBD in serum and milk were assessed by ELISA. Neutralizing antibody activity was assessed by Luciferase Assay System.	Pfizer–BioNTech and Moderna.	Maternal antibody titer, systemic adverse events, cord blood antibody titer, and breast milk antibody titer.
Shanes et al., 2021 <sup>13</sup>	Cohort	United States	1st vaccine-to-delivery interval (Mean±SD) 45.96±24.3 days	Received vaccine: 84 Neither vaccinated nor infected:	0	Vaccinated 33.7±3.1 Not vaccinated: 32.5±4.8	NR	Antibody testing from plasma used a paramagnetic particle, chemiluminescent immunoassay.	mRNA vaccines.	Maternal antibody titer and placental finding.

				116						
Prabhu et al, 2021 <sup>14</sup>	Cohort	United States	NR	Received vaccine: 122	Neonates: 122	NR	NR	Semi-quantitative testing for RBD used (ET HealthCare) 3 on sera of maternal peripheral blood and neonatal cord blood.	Pfizer–BioNTech and Moderna.	Maternal antibody, Neonatal IgG, Maternal antibody vs neonatal IgG, Placental transfer ratio.
Gill and Jones, 2021 <sup>15</sup>	Case Report	United States	Gestational age at first vaccine dose: 32.9 weeks	Received vaccine: 1	0	34 years	NR	Cord blood and maternal blood .	Pfizer–BioNTech	Maternal antibody, cord blood IgG
Kadali et al, 2021 <sup>16</sup>	Cross-sectional study	United States	NR	Pregnant, received vaccine: 38	Non pregnant, received vaccine: 991	NR	NR	Independent online survey questionnaire (Survey Monkey, San Mateo, CA). Anonymous responses about the side effects were collected from HCWs representing various parts of the country	Pfizer–BioNTech and Moderna.	Local adverse events, and systemic adverse events.
Rottenstreich et al., 2021 <sup>17</sup>	Cohort	Israel	1st vaccine-to-delivery interval (Median (IQR)) 33 (30-37) days	20	0	32 (28-37) years	NR	Antibody in maternal and cord blood sera were assessed by chemiluminescent microparticle immunoassay (CMIA).	SARS-CoV-2 BNT162b2 mRNA vaccine.	Maternal IgG, cord blood IgG and placental transfer ratio.
Mithal et al., 2021 <sup>18</sup>	Prospective case series	United States	Gestational age at first vaccine dose (Mean±SD) 33±2 weeks	Received vaccine: 27	Neonates: 28 (1 twin pair)	33±3 years;	NR	Maternal blood and umbilical cord blood using paramagnetic particle, chemiluminescent immunoassay.	Pfizer–BioNTech, Moderna, and unknown.	Maternal antibody titer, positive IgM rate, positive IgG rate, IgG transfer outcomes, and Infant IgG outcomes.
Theiler et al., 2021 <sup>19</sup>	Cohort	United States	Gestational age at first vaccine dose (Median (IQR)) 32 (13.9-40.6) days	Received vaccine: 140 Had Covid-19 infection during pregnancy: 212	0	31.8±3.72 years	30.0±5.32 years	Electronic medical record from Mayo Clinic	Pfizer–BioNTech and Moderna.	Infection rate, Maternal and delivery outcome, and length of stay.

Beharier <i>et al.</i> , 2021 <sup>20</sup>	Cohort	Israel	Gestational age at first vaccine dose (Mean±SD) 34.5±7.5 weeks	Received vaccine: 92 Neither vaccinated nor infected: 66 Past SARS-CoV 2 infections: 74	0	Vaccinated 31.7±5.8 years Not vaccinated, not infected: 31.6±5.8 years Past SARS-CoV 2 infections: 28.8±5.8 years	NR	Maternal and fetal blood samples Sera IgG and IgM titers were measured using bead-based multiplex assay (for S1, S2, RBD and N).	Pfizer–BioNTech.	Temporal dependence in pregnant women, temporal dependence in neonates, maternal IgG between vaccinated vs PCR-positive, and Maternal-fetal IgG response to infection and vaccination correlation.
Paul and Chad, 2021 <sup>21</sup>	Case Report	United States	36.4 weeks	Received vaccine: 1	0	NR	NR	The Electro-chemiluminescence Immunoassay (ECLIA) uses a recombinant protein representing the RBD	Moderna.	Cord blood antibody level.

Reference	Infection rate N (%)		Maternal SARS-CoV 2 antibody titer (Mean ± SD or Median (IQR))		Local adverse event N (%)	
	Intervention	Comparison	Pregnant	Non-Pregnant	Pregnant	Non-Pregnant
Shimabukuro <i>et al.</i> , 2021 <sup>10</sup>	<p><b>Pfizer–BioNTech vaccine</b> ≤14 days after first eligible dose of vaccination: 3 (0.1%)</p> <p>&gt;14 days after first eligible dose of vaccination: 9 (0.4%)</p>	<p><b>Moderna vaccine</b> ≤14 days after first eligible dose of vaccination: 7 (0.4%)</p> <p>&gt;14 days after first eligible dose of vaccination: 3 (0.2%)</p>	NR	NR	<p><b>Pfizer–BioNTech vaccine (1<sup>st</sup> dose vs 2<sup>nd</sup> dose)</b> Injection-site pain: 7602 (84%) vs 5886 (89%) Injection-site redness: 160 (2%) vs 169 (3%) Injection-side itching: 103 (1%) vs 109 (2%)</p> <p><b>Moderna vaccine (1<sup>st</sup> vs 2<sup>nd</sup> dose)</b> Injection-site pain: 7360 (93%) vs 5388 (96%) Injection-site redness: 348 (4%) vs 491 (9%) Injection-side itching: 157 (2%) vs 193 (3%)</p>	NR
Gray <i>et al.</i> , 2021 <sup>11</sup>	NR	NR	NR	NR	<p><b>First dose vaccine</b> Injection-site soreness: 73 (88%) Injection site reaction or rash: 1 (1%)</p> <p><b>Second dose vaccine</b> Injection-site soreness: 44 (57%) Injection site reaction or rash: 1 (1%)</p>	<p><b>First dose vaccine</b> Injection-site soreness: 12 (75%) Injection site reaction or rash: 0 (0%)</p> <p><b>Second dose vaccine</b> Injection-site soreness: 12 (75%) Injection site reaction or rash: 0 (0%)</p>
Collier <i>et al.</i> , 2021 <sup>12</sup>	NR	NR	<p><b>Vaccinated</b> RBD IgG (median): 27,601 AU Neutralizing Ab (median): 910 AU</p> <p><b>Infected</b> RBD IgG (median): 1,321 AU Neutralizing Ab (median): 148 AU</p>	<p><b>Vaccinated</b> RBD IgG (median): 37,839 AU Neutralizing Ab (median): 901 AU</p> <p><b>Infected</b> RBD IgG (median): 771 AU Neutralizing Ab (median): 193 AU</p>	NR	NR
Shanes <i>et al.</i> , 2021 <sup>13</sup>	NR	NR	<p><b>Vaccinated</b> RBD IgG: 22.8±14.5 RBD IgM: 4.1±13.2</p> <p><b>Unvaccinated</b> RBD IgG: 0.04±0.05</p>	NR	NR	NR

			RBD IgM: 0.19±0.12			
Prabhu <i>et al.</i> , 2021 <sup>14</sup>	NR	NR	NR	NR	NR	NR
Gill and Jones, 2021 <sup>15</sup>	NR	NR	SARS-CoV-2 IgG titer: 1:25600 (+)	NR	NR	NR
Kadali <i>et al.</i> , 2021 <sup>16</sup>	NR	NR	NR	NR	Sore arm or pain: 37 (97%) Itching: 2 (5%) Muscle spasm: 1 (3%)	Sore arm or pain: 894 (90%) Itching: 98 (10%) Muscle spasm: 103 (10%)
Rottenstreich <i>et al.</i> , 2021 <sup>17</sup>	NR	NR	Anti-S IgG: 319 (211-1033) AU/mL  Anti-RBD-Specific IgG: 11,150 (6154-17,575) AU/mL	NR	NR	NR
Mithal <i>et al.</i> , 2021 <sup>18</sup>	NR	NR	NR	NR	NR	NR
Theiler <i>et al.</i> , 2021 <sup>19</sup>	<p><b>Vaccinated:</b> None: 138 (99%) Trimester 1: 0 (0%) Trimester 2: 2 (1%) Trimester 3: 0 (0%)</p> <p>p=0.0004</p>	<p><b>Not vaccinated:</b> None: 1652 (89%) Trimester 1: 26 (1%) Trimester 2: 84 (5%) Trimester 3: 100 (5%)</p>	NR	NR	NR	NR
Beharier <i>et al.</i> , 2021 <sup>20</sup>	NR	NR	NR	NR	NR	NR
Paul and Chad, 2021 <sup>21</sup>	NR	NR	NR	NR	NR	NR

Reference	Systemic adverse events N (%)		Others
	Pregnant	Non-Pregnant	
Shimabukuro et al, 2021 <sup>10</sup>	<p><b>Pfizer–BioNTech vaccine (1<sup>st</sup> dose vs 2<sup>nd</sup> dose)</b>            Fatigue: 2406 (27%) vs 4231 (64%)            Headache: 1497 (17%) vs 3138 (47%)            Myalgia: 795 (9%) vs 2916 (44%)            Chills: 254 (3%) vs 1747 (26%)            Fever or felt feverish: 256 (3%) vs 1648 (25%)            Measured temperature ≥ 38°C: 30 (0%) vs 315 (5%)            Nausea: 492 (5%) vs 1356 (20%)</p> <p><b>Moderna vaccine (1<sup>st</sup> vs 2<sup>nd</sup> dose)</b>            Fatigue: 2616 (33%) vs 4541 (81%)            Headache: 1581 (20%) vs 3662 (65%)            Myalgia: 1167 (15%) vs 3722 (66%)            Chills: 442 (6%) vs 2755 (49%)            Fever or felt feverish: 453 (6%) vs 2594 (46%)            Measured temperature ≥ 38°C: 62 (1%) vs 664 (12%)            Nausea: 638 (8%) vs 1909 (34%)</p>	NR	<p><b>Maternal and delivery outcomes</b></p> <p>Pregnancy loss among complete pregnancy (N (%))</p> <ul style="list-style-type: none"> <li>- Abortion: 104 (12.6%)</li> <li>- Stillbirth: 1 (0.1%)</li> </ul> <p>Neonatal outcome among live-born infants (N (%))</p> <ul style="list-style-type: none"> <li>- Preterm birth: 60 (9.4%)</li> <li>- Small size for gestational age: 23 (3.2%)</li> <li>- Congenital anomalies (N=16; 2.2%)</li> <li>- Neonatal death (N=0; 0%)</li> </ul>
Gray et al, 2021 <sup>11</sup>	<p><b>First dose vaccine</b>            Headache: 7 (8%)            Muscle aches: 2 (2%)            Fatigue: 12 (14%)            Fever or chills: 1 (1%)</p> <p><b>Second dose vaccine</b>            Headache: 25 (32%)            Muscle aches: 37 (48%)            Fatigue: 41 (53%)</p>	<p><b>First dose vaccine (N (%))</b>            Headache: 5 (31%)            Muscle aches: 2 (12%)            Fatigue: 6 (38%)            Fever or chills: 1 (6%)</p> <p><b>Second dose vaccine (N (%))</b>            Headache: 6 (38%)            Muscle aches: 7 (44%)            Fatigue: 9 (56%)</p>	<p><b>Adverse pregnancy outcome (N (%))</b></p> <p>Fetal growth restriction: 0 (0%)            Preeclampsia/gestational hypertension: 0 (0%)            Preterm delivery (spontaneous): 1 (8%)            Preterm delivery (medically indicated): 0 (0%)</p> <p><b>Composite infant morbidity (N (%))</b></p> <p>Supplemental oxygen/CPAP: 1 (8%)            TTN: 1 (8%)            Special care nursery admission: 0 (0%)</p>

	<p>Fever or chills: 25 (32%)</p>	<p>Fever or chills: 8 (50%)</p>	<p>NICU admission: 2 (15%)          Respiratory distress syndrome: 0 (0%)          Necrotizing enterocolitis: 0 (0%)          Sepsis: 0 (0%)          Assisted ventilation: 0 (0%)          Seizure: 0 (0%)          Grade 3/4 intraventricular hemorrhage: 0 (0%)          Death: 0 (0%)  <b>IgG Spike response</b>          Pregnant V1 vs Pregnant V0: P&lt;0.0001          Pregnant V2 vs Pregnant V0: P&lt;0.0001          Pregnant V2 vs Pregnant V1: P&lt;0.05          Cord blood IgG titer vs time from maternal V2 corr.(r): 0.8; p=0.01          Vaccinated pregnant vs natural infection pregnant titer: P&lt;0.0001  <b>IgG RBD response</b>          Pregnant V1 vs Pregnant V0: P&lt;0.01          Pregnant V2 vs Pregnant V0: P&lt;0.0001          Pregnant V2 vs Pregnant V1: P&lt;0.001          Cord blood IgG titer vs time from maternal V2 corr.(r): 0.50; p=0.17  <b>Neutralizing antibody titer (umbilical cord vs maternal serum)</b>          Medial (IQR): 104 (61.2-188.2) vs 52.3 (11.7-69.6); P=0.05  <b>Antibodies transfer from maternal to cord blood</b>          Spike IgG3 (r): 0.93; p=0.03          RBD IgG3 (r): 0.81; p=0.07</p>
--	----------------------------------	---------------------------------	--

Collier et al, 2021 <sup>12</sup>	Fever after first dose: 0 (0%) Fever after second dose: 4 (14%)	Fever after first dose: 1 (2%) Fever after second dose: 27 (52%)	<p><b>RBD IgG titer median (mother serum vs cord blood)</b> Vaccinated: 14953 vs 19873 Infected: 1324 vs 635</p> <p><b>Neutralizing antibodies titer median (mother serum vs cord blood)</b> Vaccinated: 1016 AU vs 324 Infected: 151 vs 164</p> <p><b>RBD IgG against SARS-CoV-2 Variants of Concern</b> Binding antibody responses were comparable against wild type USA-WA1/2020 and B.1.1.7 RBD proteins in nonpregnant, pregnant, and lactating women and in infant cord samples but were lower for the B.1.351 RBD protein.</p>
Shanes et al, 2021 <sup>13</sup>	NR	NR	NR
Prabhu et al, 2021 <sup>14</sup>	NR	NR	<p><b>Positive maternal antibody rate</b> Women with detectable: - IgG &amp; IgM (N (%)): 87 (71%) - IgG only (N (%)): 19 (16%) Women with no detectable IgG &amp; IgM (N (%)): 16 (13%)</p> <p><b>Positive neonatal antibody rate</b> IgG from whom the mother received: - One vaccine dose (N (%)): 24 (43.6%) - Two vaccine doses (N (%)): 65 (98.5%)</p> <p><b>Placental transfer outcome</b> Maternal IgG and neonatal IgG correlation (R): 0.89, p&lt;2.2 e-16 Placental transfer ratio and weeks elapsed since maternal vaccination dose 2 correlation (R): 0.8, p=2.6 e-16</p>
Gill and Jones, 2021 <sup>15</sup>	NR	NR	<p><b>Cord blood antibody:</b> SARS-CoV-2 IgG titer: 1:25600 (+)</p>
Kadali et al.,	<b>Pregnant</b>	<b>Non pregnant</b>	NR

2021 <sup>16</sup>	<p>Fatigue: 22 (58%)  Headache: 19 (50%)  Chills: 18 (47%)  Myalgia: 13 (34%)  Nausea: 11 (29%)  Fever: 6 (16%)  Seizure*: 1 (3%)</p>	<p>Fatigue: 643 (65%)  Headache: 519 (52%)  Chills: 424 (43%)  Myalgia: 488 (49%)  Nausea: 211 (21%)  Fever: 279 (28%)  Seizure*: 0 (0%)</p>	
Rottenstreich <i>et al.</i> , 2021 <sup>17</sup>	NR	NR	<p><b>Cord-Blood level</b>  Anti-S IgG (median (IQR)): 193 (111-260) AU/mL  Anti-RBD-specific IgG (median (IQR)): 3494 (1817-6163) AU/mL</p> <p><b>Placental transfer ratio</b>  Anti-S IgG (median (IQR)): 0.44 (0.25-0.61)  Anti-RBD-specific IgG (median (IQR)): 0.34 (0.27-0.56)</p>
Mithal <i>et al.</i> , 2021 <sup>18</sup>	NR	NR	<p><b>Positive IgM rate</b>  Maternal serum (N (%)): 15 (56%)  Cord blood (N (%)): 0 (0%)</p> <p><b>Positive IgG rate</b>  Maternal serum (N (%)): 26 (96%)  Cord blood (N (%)): 25 (89%)</p> <p><b>IgG transfer outcomes</b>  Maternal to infant (mean±SD): 1.0±0.6  Latency from vaccination to delivery vs IgG transfer ratio correlation (β): 0.2 (95%CI 0.1-0.2)</p> <p><b>Infant IgG outcomes</b>  Having received the 2<sup>nd</sup> vaccine dose vs infant IgG level correlation (β): 19.0 (95%CI 7.1-30.8)  Latency from vaccination to delivery vs infant IgG level correlation (β): 2.9 (95%CI 0.7-5.1)</p>
Theiler <i>et al.</i> ,	NR	NR	<b>Maternal and delivery outcome N (%) (vaccinated vs</b>

2021<sup>19</sup>

**unvaccinated)**

Adverse outcomes index (AOI): 91 (5%) vs 7 (5%); p= 0.9524  
AOI excluding laceration: 55 (3%) vs 5 (4%); p= 0.6071  
Hypoxic, ischaemic encephalopathy: 1 (0%) vs 0 (0%); p= 1  
Uterine rupture, AOI: 1 (0%) vs 0 (0%); p= 1  
Unplanned ICU admission: 2 (0%) vs 1 (1%); p= 0.1956  
Birth trauma: 11 (1%) vs 0 (0%); p= 1  
Return to OR: 6 (0%) vs 1 (1%); p= 0.3985  
NICU admit > 2500g: 11 (1%) vs 1 (1%); p= 0.5821  
5 Minute apgar <7: 38 (2%) vs 3 (2%); p= 0.7617  
Hemorrhage with transfusion: 5 (0%) vs 1 (1%); p= 0.3531  
Third- or fourth-degree laceration: 37 (2%) vs 2 (1%); p= 1  
Mode of delivery: p= 0.6517  
- spontaneous vaginal: 1238 (66%) vs 89 (64%)  
- operative vaginal: 69 (4%) vs 7 (5%)  
- cesarean: 555 (30%) vs 44 (31%)  
Gestational age delivery: p=0.7028  
- 37+: 1703 (91%) vs 127 (91%)  
- 32-36.9: 134 (7%) vs 10 (7%)  
- 24-31.9: 21 (1%) vs 2 (1%)  
- <24: 4 (0%) vs 1 (1%)  
Quantitative blood loss > 1000mL: 56 (3%) vs 6 (4%); p= 0.4452  
Transfusion: 241 (13%) vs 25 (18%); p= 0.1198  
Thromboembolism: 2 (0%) vs 0 (0%); p= 1  
Stroke: 1 (0%) vs 0 (0%); p= 1  
Eclampsia/pre-eclampsia (+/-72 h. of delivery): 23 (1%) vs 1(1%); p=1  
Gestational hypertension: 225 (12%) vs 19 (14%); p= 0.6038  
Low birth weight (<2500g): 121 (6%) vs 11 (8%); p= 0.5321  
Very low birth weight (<1500g): 21 (1%) vs 3 (2%); p= 0.2332

Beharier <i>et al.</i> , 2021 <sup>20</sup>	NR	NR	<p>StillBirth: 6 (0%) vs 0 (0%); p= 1</p> <p><b>Temporal dependence in pregnant women</b></p> <p>After infection: A gradual rise in IgG humoral response (Anti- S1, S2, RBD and N) was detected during the first 45 days after infection.</p> <p>After the first dose: In the same period, vaccinated participants receiving the first BNT162b2 dose showed a rapid IgG response to S1, S2, RBD but not N, resulting in high titer values by day 15 after the first dose.</p> <p>After the second dose: A further rise in IgG was observed following the second dose.</p> <p><b>Temporal dependence in neonates</b></p> <p>After the first dose: The temporal dependence of fetal IgG for S1, S2 and RBD after vaccination trailed after the maternal IgG showing a significant response already by day 15.</p> <p>After the second dose: A further increase was observed following the second vaccination dose.</p> <p><b>Maternal IgG between vaccinated vs PCR-positive</b></p> <p>S1 IgG: higher in vaccination (P=0.0009) RBD IgG: higher in vaccination (P=0.0045) S2 IgG: higher in PCR-positive (P=0.016) N IgG: higher in PCR-positive (P=&lt;0.0001)</p> <p><b>Maternal to fetal IgG transfer ratio for S1, S2, RBD, and N</b></p> <p>PCR-positive vs N<sup>-</sup> group: Significant differences were found for S1, S2 and RBD (P&lt;0.0002)</p> <p>PCR-positive vs N<sup>+</sup> group: For all antibodies did not differ (P=0.4577)</p> <p><b>Maternal-fetal IgG response to infection and vaccination</b></p>
---	----	----	--

			<p><b>correlation</b></p> <p>S1 IgG: R<sup>2</sup>= 0.9443; Adjusted R<sup>2</sup>= 0.9438; P&lt;0.0001</p> <p>S2 IgG: R<sup>2</sup>= 0.9353; Adjusted R<sup>2</sup>= 0.9348; P&lt;0.0001</p> <p>RBD IgG: R<sup>2</sup>= 0.9200; Adjusted R<sup>2</sup>= 0.9194; P&lt;0.0001</p> <p>N IgG: R<sup>2</sup>= 0.9366; Adjusted R<sup>2</sup>= 0.9361; P&lt;0.0001</p> <p>Infection vs vaccination maternal-fetal IgG response</p> <ul style="list-style-type: none"> <li>- S1 IgG: P=0.2936</li> <li>- S2 IgG: P=0.4212</li> <li>- RBD IgG: P=0.0702</li> <li>- N IgG: P=0.7616</li> </ul>
Paul and Chad, 2021 <sup>21</sup>	NR	NR	<p><b>Cord blood Antibody</b></p> <p>IgG concentration: 1.31 U/mL</p>

198 Abbreviations: NR (not reported); AU (arbitrary unit)

199 \* It reached statistical significance (p=0.0369). However, the participant with a report of seizure has a known history of seizure disorder and her anticonvulsant blood level

200 was reported as borderline low.

201 **Infection Rate**

202 Among pregnant women who received the Pfizer–BioNTech vaccine, 0.1% (3/2136) of pregnant  
203 women experienced Covid-19 infection within 14 days from vaccination and 0.4% (9/2136) after 14  
204 days from vaccination. Additionally, among pregnant women who received Moderna vaccines,  
205 0.4% (7/1822) of pregnant women experienced Covid-19 infection within 14 days from vaccination  
206 and 0.2% (3/1822) after 14 days from vaccination.<sup>10</sup> Among unvaccinated vs vaccinated pregnant  
207 women, vaccination significantly reduced the risk of future infection ( $p=0.0004$ ) and all infection  
208 cases, reported in the trimester I of vaccinated women, occurred prior to the first vaccination dose.<sup>19</sup>

209 **Maternal antibody response**

210 Vaccination induced IgG and IgM production in 71% (87/122) pregnant women; 16% (19/122)  
211 pregnant women produced only IgG whilst 13% (16/122) had neither detectable IgG nor IgM.<sup>14</sup>  
212 Vaccination provided a rapid immunologic response after the first dose while infection provided a  
213 gradual immunologic response. Moreover, administration of the second dose can further increase  
214 the IgG level among vaccinated women.<sup>11,20</sup> Spike- and RBD- IgG titer rose rapidly after prime  
215 dose ( $p<0.0001$  and  $p<0.01$ , respectively); and after receiving booster, it became higher than that of  
216 the prime dose ( $p<0.05$  and  $p<0.001$ , respectively).<sup>11</sup>

217 Vaccination elicited IgG responses against S1, S2, and RBD but not N protein. Meanwhile,  
218 infection elicited all IgG responses against S1, S2, RBD, and N protein. Among vaccinated  
219 pregnant women, S1 IgG and RBD IgG levels were higher ( $p=0.0009$  and  $p=0.0045$ , respectively).  
220 Yet, S2 IgG and N IgG were higher in infected pregnant women ( $p=0.016$  and  $p<0.0001$ ,  
221 respectively).<sup>20</sup> Meanwhile, Gray et al., (2021) reported that Spike IgG titer is higher in vaccination  
222 than that of natural infection in pregnant women.<sup>11</sup>

223 Maternal SARS-CoV-2 spike protein IgG levels between vaccinated and uninfected  
224 unvaccinated pregnant women are  $22.8\pm 14.5$  AU and  $0.04\pm 0.05$  AU, respectively ( $p<0.001$ ). While  
225 for the IgM levels are  $4.1\pm 13.2$  AU and  $0.19\pm 0.12$  AU, respectively ( $p=0.001$ ).<sup>13</sup> Among pregnant  
226 women that received two vaccine doses, anti-spike-protein IgG concentration median is 319 (211-  
227 1033) AU/mL and anti-RBD-Specific IgG concentration median is 11150 (6154-17575) AU/mL.<sup>17</sup>  
228 Meanwhile, in two women that only received one dose of vaccine, the anti-spike-protein IgG  
229 concentrations are 50 AU/mL and 52 AU/m; and the anti-RBD-Specific IgG concentrations are 293  
230 AU/mL and 1137 AU/mL.<sup>17</sup>

231 Antibody response in pregnant and non-pregnant women was evaluated by Collier et al.,  
232 (2021).<sup>12</sup> The study reported the median of IgG levels between vaccinated and infected pregnant  
233 women. The RBD IgG titers were 27601 and 1321, respectively; while the neutralizing antibody

234 titers were 910 and 148, respectively. The median of RBD IgG titers between vaccinated and  
235 infected non-pregnant women were 37839 and 771, respectively; while for the Neutralizing  
236 antibody were 901 and 193, respectively.<sup>12</sup>

### 237 **Antibody transfer**

238 A prospective case series reported that the IgG was detected in 89% (25/28) of cord blood, but none  
239 had detectable IgM.<sup>18</sup> Moreover, antibody against SARS-CoV-2 RBD and neutralizing antibody  
240 was observed in cord blood. On vaccinated women, the maternal vs cord blood RBD IgG was  
241 14953 AU vs 19873 AU, whilst for the neutralizing antibody was 1016 AU vs 324 AU.<sup>12</sup> IgG  
242 against S protein was also detected in cord blood with concentration of 193 (111-260) AU/mL and  
243 its transfer ratio was 0.44 (0.25-0.61). Furthermore, the concentration of IgG against RBD was 3494  
244 (1817-6163) AU/mL and its transfer ratio was 0.34 (0.27-0.56).<sup>17</sup>

245 Two different case report studies from mother who received two doses of BNT162b2 vaccine  
246 and mother who received one dose of Moderna vaccine, respectively, reported that SARS-CoV-2  
247 specific IgG was detected in maternal blood and cord blood at a titer 1:25.600, while cord blood  
248 IgG concentration were detected at level of 1.31 U/mL.<sup>15,21</sup>

249 Regarding the number of doses received, antibody was detected in 98.5% (65/67) neonates  
250 from whom the mother received two doses of vaccine. From mothers who received only one  
251 vaccine dose, only 43.6% (24/55) neonates whose antibody was detected.<sup>14</sup> Having received the  
252 second vaccine dose was positively correlated with infant IgG level ( $\beta=19.0$  (95%CI 7.1-30.8)).<sup>18</sup> In  
253 addition to doses, the interval from vaccination to delivery was correlated with IgG transfer ratio  
254 and infant IgG level. Increased latency from vaccination to delivery was positively correlated with  
255 IgG transfer ratio ( $\beta=0.2$  (95%CI 0.1-0.2)) and infant IgG level ( $\beta=2.9$  (95%CI 0.7-5.1)).<sup>18</sup> For  
256 maternal-fetal IgG response, there was no statistical difference between vaccination and SARS-  
257 CoV-2 infection for S1 IgG ( $p=0.2936$ ), S2 IgG ( $p=0.4212$ ), RBD IgG ( $p=0.0702$ ), and N IgG  
258 ( $p=0.7616$ ).<sup>20</sup>

### 259 **Local adverse events**

260 Among pregnant women, injection-site pain is the most common adverse event in both the Pfizer–  
261 BioNTech and Moderna vaccines. Following the Pfizer–BioNTech vaccination, as many as 84%  
262 (7602/9052) in the first dose and 89% (5886/6638) in the second dose experienced injection-site  
263 pain. While for the Moderna vaccine, 93% (7360/7930) and 96% (5388/5635) following the first  
264 and the second dose, respectively, experienced injection-site pain.<sup>10</sup> It was also reported 88%  
265 (73/84) pregnant women experienced injection-site soreness following the first dose vaccination

266 and 57% (44/84) following the second dose. Additionally, 75% (12/75) non-pregnant women  
267 experienced injection-site soreness after the first and the second dose of vaccine.<sup>11</sup>

268 Between pregnant and non-pregnant women, sore arms or pain were observed in 97% (37/38)  
269 pregnant women and 90% (894/991) non-pregnant women following Pfizer–BioNTech and  
270 Moderna vaccination.<sup>16</sup>

### 271 **Systemic adverse event**

272 Systemic adverse events between two doses of Pfizer–BioNTech and Moderna were reported.  
273 Following Pfizer–BioNTech the first vs the second dose of vaccine, six most experienced systemic  
274 adverse events were fatigue (27% (2406/9052) vs 64% (4231/6638)); headache (17% (1497/9052)  
275 vs 47% (3138/6638)), myalgia (9% (795/9052) vs 44% (2916/6638)), chills (3% (254/9052) vs 26%  
276 (1747/6638)), fever (3% (256/9052) vs 25% (1648/6638)), and nausea (5% (492/9052) vs 20%  
277 (1356/6638)). For the Moderna vaccine, fatigue (33% (2616/7930) vs 81% (4541/5635)), headache  
278 (20% (1581/7930) vs 65% (3662/5635)), myalgia (15% (1167/7930) vs 66% (3722/5635)), chills  
279 (6% (442/7930) vs 49% (2755/5635)), fever (6% (453/7930) vs 46% (2594/5635)), and nausea (8%  
280 (638/7930) vs 34% (1909/5635)). Numerically, the incidence of each event is higher in the second  
281 dose. Moreover, the Moderna vaccine had more systemic adverse events than that of the Pfizer–  
282 BioNTech vaccine.<sup>10</sup> Seizure was reported in a woman who received mRNA vaccine (p=0.0369),  
283 but it was known that the patient has a history of seizure disorder and the anticonvulsant level in the  
284 blood was borderline low.<sup>16</sup>

### 285 **Maternal outcomes**

286 Maternal outcomes were described as pregnancy outcomes and delivery outcomes. Compared to  
287 unvaccinated pregnancy, vaccination did not significantly affect pregnancy or delivery outcomes.  
288 The adverse outcome index between vaccinated and unvaccinated pregnancy was insignificant  
289 (p=0.9524). Between these group, there were no statistical difference in pregnancy outcome such as  
290 eclampsia/pre-eclampsia (p=1), gestational hypertension (p=0.6038), gestational age (p=0.7028),  
291 and thromboembolism incidence (p=1).<sup>19</sup> Moreover, the abortion rate was reported at 12.6%  
292 (104/827) and 9.4% (60/636) had preterm birth. Statistically, vaccination also did not affect delivery  
293 outcomes such as birth trauma (p=1), uterine rupture (p=1), unplanned ICU admission (p=0.1956),  
294 quantitative blood loss>1000mL (p=0.4452) or hemorrhage with transfusion (p=0.3531), mode of  
295 delivery (p=0.6517), and stillbirth (p=1).<sup>19</sup>

### 296 **Neonatal outcomes**

297 As many as 15% (2/13) required NICU admission, 8% (1/13) experienced TTN, and 8% (1/13)  
298 required supplemental oxygen or CPAP. Preterm delivery was reported in 8% (1/13) of women.<sup>11</sup>  
299 Moreover, 0.1% (1/725) were stillbirth, 3.2% (23/724) had small size for gestational age and 2.2%  
300 (16/724) had congenital anomalies. No neonatal death was reported.<sup>10</sup> On statistical analysis, NICU  
301 admission (p=0.5821), 5 minute Apgar <7 (0.7617), hypoxic ischemic encephalopathy (p=1), and  
302 low birth weight (p= 0.5321) or very low birth weight (p= 0.2332), did not differ significantly  
303 between vaccinated and unvaccinated women.<sup>19</sup>

## 304 **DISCUSSION**

### 305 **Main Finding**

306 It has been described that Pfizer-BioNTech and Moderna vaccines were efficacious for preventing  
307 future SARS-CoV-2 infection in pregnant women.<sup>19</sup> Following Pfizer-BioNTech and Moderna  
308 vaccinations, the vast majority of pregnant women will have injection-site pain or soreness.<sup>10,11,16</sup>  
309 Some most-experienced systemic adverse events were fatigue, headache, chills, myalgia, fever, and  
310 nausea.<sup>10,16</sup> The incidence of these systemic adverse events were higher after the second dose  
311 compared to the first dose.<sup>10-12</sup> Numerically, there were more individuals who experienced these  
312 systemic adverse events in Moderna vaccine group than that of Pfizer-BioNTech group.<sup>10</sup> The  
313 adverse events were not statistically differ between pregnant and non pregnant women, except  
314 seizure. However, the woman was known to have a history of seizure disorder and the  
315 anticonvulsant level was measured borderline-low.<sup>19</sup> Interestingly, the pregnancy, delivery, and  
316 neonatal outcomes did not differ between pregnant and non pregnant women.<sup>19</sup>

317 Maternal antibody response has been described formed following vaccination.<sup>11-15,17,18,20</sup>  
318 Through vaccination, antibody response was formed rapidly; while through vaccination it was  
319 formed gradually.<sup>20</sup> The number of IgG and IgM against SARS-CoV-2 were significantly increased  
320 after vaccination. The response was increased after a booster was given.<sup>11,13</sup> Although vast majority  
321 of pregnant women had IgG seroconversion, IgM seroconversions were observed in a minority of  
322 pregnant women.<sup>18</sup> After vaccination, IgG against S1, S2 and RBD formed whilst IgG against S1,  
323 S2, RBD and N protein formed following natural infections. Moreover, S1- and RBD- IgG were  
324 observed higher in vaccinated pregnant women. Meanwhile the S2- and N- IgG were observed  
325 higher in naturally infected pregnant women.<sup>20</sup> Also, the RBD IgG and neutralizing antibody was  
326 higher in vaccinated individuals than that of naturally infected.<sup>12</sup>

327 Antibody transfer was also reported.<sup>12,14,15,17,18,20,21</sup> Cord blood antibody and maternal antibody  
328 levels were about equal.<sup>18</sup> Additionally, latency and number of doses were correlated with the

329 antibody transfer strength.<sup>14,18</sup> The longer the latency, the better the antibody transfer and the higher  
330 the IgG.<sup>18</sup> A mother who received two doses of vaccines would have her infant getting higher IgG  
331 levels.<sup>18</sup> Between infection and vaccination, there was no difference in maternal-fetal IgG  
332 response.<sup>20</sup>

### 333 **Finding on other studies**

334 A sufficient herd immunity threshold in a population will provide indirect protection for susceptible  
335 individuals from infected hosts.<sup>22</sup> The threshold varies across different infections.<sup>23-25</sup> In Covid-19,  
336 it was said that for a vaccine with 100% efficacy and providing life-long protection, we would need  
337 60-75% herd immunity. This required number would be increased if the vaccine efficacy was  
338 reduced to 85%; a 75-90% herd immunity would be required.<sup>26</sup> Although we described that Pfizer-  
339 BioNTech and Moderna vaccines are efficacious to prevent future SARS-CoV-2 infection, whether  
340 the efficacy of these vaccines is reduced in pregnancy remains unknown.

341 This herd immunity threshold may also vary across populations. It depends on some factors--  
342 epidemiological factors (e.g., population density and transmission dynamics) and immunological  
343 factors (e.g., immune stats of population).<sup>22</sup> An approach to achieve this threshold is through mass  
344 vaccination campaigns.<sup>22</sup> Thus, high vaccination coverage is important for achieving sufficient herd  
345 immunity.<sup>27,28</sup>

346 On note, not only pregnant individuals but also those who were not pregnant will experience  
347 these adverse reactions as well. In Moderna and Pfizer-BioNTech studies where pregnant women  
348 and children were excluded, the incidence of systemic adverse events increased after the second  
349 dose of vaccine.<sup>29,30</sup> Following the Moderna vaccine booster, local pain was experienced by 83.2-  
350 89.9% of individuals, followed by fatigue (58.3-65.3%) and headache (46.2-62.8%). Meanwhile,  
351 there were 10.0-15.5% who experienced fever. These were generally resolved within 3.1-3.2 days.<sup>29</sup>  
352 Following the Pfizer-BioNTech vaccine booster, injection-site pain was experienced by 66%-78%  
353 individuals, followed by fatigue (51-59%) and headache (39-52%). Meanwhile, fever was  
354 experienced by 11-16% of individuals. These adverse events were transient, resolved within 1-2  
355 days.<sup>30</sup>

356 Safety is an important concern for Covid-19 vaccination in pregnant women. Based on a survey  
357 in 16 countries, pregnant women were less likely to accept vaccines for themselves. Given that a  
358 Covid-19 vaccine had 90% efficacy, 73.4% non-pregnant women intended to receive the vaccine  
359 while pregnant women were only 52%. The confidence in vaccine safety and effectiveness was one  
360 of the predictors for vaccine acceptance.<sup>31</sup> However, vaccination safety did not differ among those

361 who are pregnant or not. Moreover, vaccination did not affect pregnancy, delivery, and pregnancy  
362 outcomes. On the other hand, some conditions during pregnancy made pregnant women susceptible  
363 to severe disease of Covid-19.<sup>32</sup>

364 During pregnancy, the upper respiratory tract was swollen and lung expansion was restricted. It  
365 makes pregnant women more susceptible to respiratory pathogens.<sup>33</sup> Moreover, pro-inflammatory  
366 phase was present in the first trimester, for the implantation of the embryo and placenta, and third  
367 trimester, to prepare for the initiation of labor.<sup>34</sup> In fact, severe Covid-19 is associated with cytokine  
368 storms.<sup>35</sup> The pro-inflammatory phase during the first and third trimester of pregnancy, made them  
369 to be more prone to severe Covid-19.<sup>36</sup>

370 Individuals with significant medical comorbidities, the elderly, and pregnant women are highly  
371 vulnerable to Covid-19 infection.<sup>37,38</sup> Although newborns and infants are less likely to get SARS-  
372 CoV-2 infections, they are more prone to severe SARS-CoV-2 infection.<sup>37,39,40</sup> Passive immunity in  
373 neonates may be potentially protective. Administration of booster doses can enhance antibody  
374 transfer which may provide a better immunity in neonates. However, this fetal passive immunity  
375 may be altered due to placental sieving<sup>41</sup>, depending on the gestational age at first vaccine dose or  
376 infection. The longer latency interval from first dose of vaccination to delivery should be required  
377 for better antibody transfer.<sup>18</sup>

378 In contrast to natural viral infection such as in Zika dan DENV,<sup>42,43</sup> antibody transfer observed  
379 following other vaccinations such as in pertussis and Influenza vaccines.<sup>44,45,46</sup> Timeframe  
380 following natural SARS-CoV-2 infection may affect antibody transfer. An earlier Covid-19  
381 infection may provide a better placental antibody transfer.<sup>20</sup> Additionally, poor placental antibody  
382 transfer was exclusively observed only in the third trimester of pregnancy, even though the maternal  
383 antibody response was significantly higher.<sup>47</sup> Natural infection may result in higher morbidity and  
384 mortality<sup>48</sup>, so vaccination should be the better option for the dyads.

385 Many SARS-CoV-2 mutations had altered Covid-19 transmissibility and, probably,  
386 severity.<sup>49,50,51</sup> Moreover, these mutations can also impact a treatment efficacy, especially  
387 monoclonal antibody treatments due to immune escape.<sup>52,53,54</sup> It had been reported, compared to the  
388 wild type of USA-WA1/2020 SARS-CoV-2, the binding strength of neutralizing antibodies formed  
389 after Pfizer and Moderna vaccination was observed 3.5- and 6- fold lower for B.1.1.7 and B.1351,  
390 respectively.<sup>12</sup> Antibody resistance against B.1.1.7 and B.1351 was also reported by another study.<sup>55</sup>  
391 In addition, in UK, it also was reported that B.1.617.2 had overtaken B.1.1.7. variants.<sup>56</sup>  
392 Maximizing the second dose vaccine coverage may provide a stronger protection against this  
393 variant.<sup>57</sup> However, we still need to know whether we would need a new vaccine or booster dose  
394 since there are evidence of reduced efficacy of currently available vaccine for these strains. This

395 problem should be taken more seriously, and other public health measures are necessary as an effort  
396 to end this pandemic.<sup>58</sup>

### 397 **Strength and limitation**

398 To the best of our knowledge, this systematic review used the most recent evidence to describe the  
399 efficacy, safety and immunogenicity of Covid-19 mRNA vaccine in pregnancy. All studies included  
400 in this review were assessed as high quality studies. However, studies are all observational studies  
401 due to no RCTs reports of Covid-19 vaccination for pregnant women yet currently available. These  
402 studies reported only from mRNA type vaccines. Moreover, all available studies that were included  
403 were only from the United States and Israel.

### 404 **CONCLUSION**

405 In this study, mRNA vaccines, especially Pfizer-BioNTech and Moderna vaccines, are efficacious  
406 for preventing future SARS-CoV-2 infections. These vaccines can induce antibody responses for  
407 pregnant women and their fetus. Pregnant women should be given two doses of vaccine for more  
408 robust maternal and fetal antibody response. Longer latency was associated with more robust fetal  
409 antibody response. Almost all pregnant women who received vaccination, either in the first or  
410 second dose, will experience injection-site pain. Furthermore, the second dose of vaccine will  
411 produce more systemic adverse events than that of the first dose and administration of Moderna  
412 vaccine was observed to have a more frequent systemic adverse events. Biologically speaking, we  
413 may conclude that for a short term, vaccination did not affect pregnancy, delivery, or neonatal  
414 outcomes.

415       **REFERENCES**

- 416       1. Dashraath P, Wong JLJ, Lim MXK, Lim LM, Li S, Biswas A, et al. Coronavirus disease 2019  
417       (COVID-19) pandemic and pregnancy. *Am J Obstet Gynecol* 2020;222(6):521-531. doi:  
418       10.1016/j.ajog.2020.03.021.
- 419       2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with  
420       2019 novel coronavirus in Wuhan, China. *The Lancet* 2020;395(10223):497–506. doi:  
421       10.1016/S0140-6736(20)30183-5.
- 422       3. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update:  
423       Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed  
424       SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-October 3,  
425       2020. *MMWR Morb Mortal Wkly Rep* 2020;69(44):1641-1647.  
426       doi:10.15585/mmwr.mm6944e3
- 427       4. Gray KJ, Bordt EA, Atyeo C, Deriso E, Akinwunmi B, Young N, et al. Coronavirus disease  
428       2019 vaccine response in pregnant and lactating women: a cohort study. *Am J Obstet Gynecol*  
429       2021;26:S0002-9378(21)00187-3. doi: 10.1016/j.ajog.2021.03.023.
- 430       5. Sutton D, Fuchs K, D'Alton M, Goffman D. Universal Screening for SARS-CoV-2 in Women  
431       Admitted for Delivery. *N Engl J Med.* 2020;28;382(22):2163-2164. doi:  
432       10.1056/NEJMc2009316
- 433       6. Yanes-Lane M, Winters N, Fregonese F, Bastos M, Perlman-Arrow S, Campbell JR, et al.  
434       Proportion of asymptomatic infection among COVID-19 positive persons and their  
435       transmission potential: A systematic review and meta-analysis. *PLoS One*  
436       2020;3;15(11):e0241536. doi: 10.1371/journal.pone.0241536.
- 437       7. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The  
438       PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*  
439       2021;372:n71. doi:10.1136/bmj.n71
- 440       8. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa  
441       Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed  
442       June 27, 2021. [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)
- 443       9. Joanna Briggs Institute. Checklist for systematic reviews and research syntheses. Accessed  
444       June 26, 2021. <https://jbi.global/critical-appraisal-tools>
- 445       10. Shimabukuro TT, Kim SY, Myers TR, Podo PL, Oduyebo T, Panagiotakopoulos L, et al.  
446       Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. *N Engl J Med*  
447       2021;384(24):2273-2282. doi:10.1056/NEJMoa2104983

- 448 11. Gray KJ, Bordt EA, Atyeo C, Deriso E, Akinwunmi B, Young N, et al. Coronavirus disease  
449 2019 vaccine response in pregnant and lactating women: a cohort study. *Am J Obstet Gynecol*,  
450 2021;S0002-9378(21)00187-3. doi:10.1016/j.ajog.2021.03.023
- 451 12. Collier AY, McMahan K, Yu J, Tostanoski LH, Aguayo R, Ansel J, et al. Immunogenicity of  
452 COVID-19 mRNA Vaccines in Pregnant and Lactating Women. *JAMA* 2021;325(23):2370-  
453 2380. doi:10.1001/jama.2021.7563
- 454 13. Shanes ED, Otero S, Mithal LB, Mupanomunda CA, Miller ES, Goldstein JA. Severe Acute  
455 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination in Pregnancy: Measures of  
456 Immunity and Placental Histopathology. *Obstet Gynecol*  
457 2021;10.1097/AOG.0000000000004457. doi:10.1097/AOG.0000000000004457
- 458 14. Prabhu M, Murphy EA, Sukhu AC, Yee J, Singh S, Eng D, et al. Antibody response to SARS-  
459 CoV-2 mRNA vaccines in pregnant women and their neonates. *bioRxiv* (preprint)  
460 2021;2021.04.05.438524.
- 461 15. Gill L, Jones CW. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)  
462 Antibodies in Neonatal Cord Blood After Vaccination in Pregnancy. *Obstet Gynecol*  
463 2021;137(5):894-896. doi:10.1097/AOG.0000000000004367
- 464 16. Kadali RAK, Janagama R, Peruru SR, Racherla S, Tirumala R, Madathala RR, et al. Adverse  
465 effects of COVID-19 messenger RNA vaccines among pregnant women: a cross-sectional  
466 study on healthcare workers with detailed self-reported symptoms. *Am J Obstet Gynecol*  
467 2021;10:S0002-9378(21)00638-4. doi:10.1016/j.ajog.2021.06.007
- 468 17. Rottenstreich A, Zarbiv G, Oiknine-Djian E, Zigron R, Wolf DG, Porat S. Efficient  
469 maternofetal transplacental transfer of anti- SARS-CoV-2 spike antibodies after antenatal  
470 SARS-CoV-2 BNT162b2 mRNA vaccination. *Clin Infect Dis* 2021;3:ciab266.  
471 doi:10.1093/cid/ciab266
- 472 18. Mithal LB, Otero S, Shanes ED, Goldstein JA, Miller ES. Cord blood antibodies following  
473 maternal coronavirus disease 2019 vaccination during pregnancy. *Am J Obstet Gynecol*  
474 2021;1:S0002-9378(21)00215-5. doi:10.1016/j.ajog.2021.03.035
- 475 19. Theiler RN, Wick M, Mehta R, Weaver A, Virk A, Swift M. Pregnancy and birth outcomes  
476 after SARS-CoV-2 vaccination in pregnancy. *medRxiv* (preprint) 2021;2021.05.17.21257337.
- 477 20. Beharier O, Plitman Mayo R, Raz T, Nahum Sacks K, Schreiber L, Suissa-Cohen Y, et al.  
478 Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2  
479 mRNA COVID-19 vaccine. *J Clin Invest* 2021;150319. doi:10.1172/JCI150319
- 480 21. Paul G, Chad R. Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal  
481 vaccination – a case report. *BMC Pediatr* 2021;21:138. doi: 10.1186/s12887-021-02618-y

- 482 22. Randolph H, Barreiro L. Herd Immunity: Understanding COVID-19. *Immunity*  
483 2020;52(5):737-741. doi:10.1016/j.immuni.2020.04.012
- 484 23. Vignesh R, Shankar E, Velu V, Thyagarajan S. Is Herd Immunity Against SARS-CoV-2 a  
485 Silver Lining ?. *Frontiers In Immunology* 2020;11:586781. doi: 10.3389/fimmu.2020.586781
- 486 24. Xia Y, Zhong L, Tan J, Zhang Z, Lyu J, Chen Y, et al. How to Understand “Herd Immunity” in  
487 COVID-19 Pandemic. *Frontiers In Cell And Developmental Biology* 2020;8:547314. doi:  
488 10.3389/fcell.2020.547314
- 489 25. Griffith B, Ulrich A, Becker A, Nederhoff D, Koch B, Awan F, et al. Does education about  
490 local vaccination rates and the importance of herd immunity change US parents’ concern about  
491 measles?. *Vaccine* 2020;38(50), 8040-8048. doi:10.1016/j.vaccine.2020.09.076
- 492 26. Anderson R, Vegvari C, Truscott J, Collyer B. Challenges in creating herd immunity to SARS-  
493 CoV-2 infection by mass vaccination. *The Lancet* 2020;396(10263):1614-1616. doi:  
494 10.1016/S0140-6736(20)32318-7
- 495 27. Lahariya C. Vaccine epidemiology: A review. *Journal Of Family Medicine And Primary Care*  
496 2016;5(1):7. doi: 10.4103/2249-4863.184616
- 497 28. Orenstein W, Seib K. Mounting a Good Offense against Measles. *New England Journal Of*  
498 *Medicine* 2014;371(18):1661-1663. doi: 10.1056/NEJMp1408696
- 499 29. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of  
500 the mRNA-1273 SARS-CoV-2 Vaccine. *New England Journal Of Medicine* 2021;384(5):403-  
501 416. doi: 10.1056/NEJMoa2035389
- 502 30. Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy  
503 of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal Of Medicine*  
504 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
- 505 31. Skjefte M, Ngirbabul M, Akeju O, Escudero D, Hernandez-Diaz S, Wyszynski D, et al.  
506 COVID-19 vaccine acceptance among pregnant women and mothers of young children: results  
507 of a survey in 16 countries. *European Journal Of Epidemiology* 2021;36(2):197-211.  
508 doi:10.1007/s10654-021-00728-6
- 509 32. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations,  
510 risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy:  
511 living systematic review and meta-analysis. *BMJ* 2020;370:m3320. doi: 10.1136/bmj.m3320
- 512 33. Cavalcante MB, Cavalcante CTMB, Sarno M, Barini R, Kwak-Kim J. Maternal immune  
513 responses and obstetrical outcomes of pregnant women with COVID-19 and possible health  
514 risks of offspring. *J Reprod Immunol* 2021;2;143:103250. doi: 10.1016/j.jri.2020.103250

- 515 34. Mor G. The unique immunological and microbial aspects of pregnancy. *Nat. Rev. Immunol*  
516 2017;17:469–482. doi: 10.1038/nri.2017.64
- 517 35. Huang C. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.  
518 *Lancet* 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5
- 519 36. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update:  
520 Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed  
521 SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-October 3, 2020.  
522 *MMWR Morb Mortal Wkly Rep* 2020;69(44):1641-1647. doi: 10.15585/mmwr.mm6944e3.
- 523 37. Levin A, Hanage W, Owusu-Boaitey N, Cochran K, Walsh S, Meyerowitz-Katz G. Assessing  
524 the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis,  
525 and public policy implications. *European Journal Of Epidemiology* 2020;35(12), 1123-1138.  
526 doi: 10.1007/s10654-020-00698-1
- 527 38. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-  
528 19 cases: A systematic literature review and meta-analysis. *Journal Of Infection*  
529 2020;81(2):e16-e25. doi: 10.1016/j.jinf.2020.04.021.
- 530 39. Liguoro I, Pilotto C, Bonanni M, Ferrari M, Pusiolo A, Nocerino A, et al. SARS-COV-2  
531 infection in children and newborns: a systematic review. *European Journal Of Pediatrics*  
532 2020;179(7):1029-1046. doi: 10.1007/s00431-020-03684-7
- 533 40. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 Among  
534 Children in China. *Pediatrics* 2020;145(6):e20200702. doi:10.1542/peds.2020-0702
- 535 41. Jennewein M, Goldfarb I, Dolatshahi S, Cosgrove C, Noelette F, Krykbaeva M, et al. Fc  
536 Glycan-Mediated Regulation of Placental Antibody Transfer. *Cell* 2019;178(1), 202-215.e14.  
537 doi: 10.1016/j.cell.2019.05.044
- 538 42. Atyeo C, Pullen K, Bordt E, Fischinger S, Burke J, Michell A, et al. Compromised SARS-  
539 CoV-2-specific placental antibody transfer. *Cell* 2021;184(3):628-642.e10. doi:  
540 10.1016/j.cell.2020.12.027
- 541 43. Haghpanah F, Lin G, Levin S, Klein E. Analysis of the potential impact of durability, timing,  
542 and transmission blocking of COVID-19 vaccine on morbidity and mortality.  
543 *Eclinicalmedicine* 2021;35:100863. doi: 10.1016/j.eclinm.2021.100863
- 544 44. Castanha PMS, Souza WV, Braga C, Araújo TVB, Ximenes RAA, Albuquerque MFPM, et al.  
545 Perinatal analyses of Zika- and dengue virus-specific neutralizing antibodies: A microcephaly  
546 case-control study in an area of high dengue endemicity in Brazil. *PLoS Negl Trop Dis*  
547 2019;11;13(3):e0007246. doi: 10.1371/journal.pntd.0007246.

- 548 45. Perret C, Chanthavanich P, Pengsaa K, Limkittikul K, Hutajaroen P, Bunn JE, et al. Dengue  
549 infection during pregnancy and transplacental antibody transfer in Thai mothers. *J Infect*  
550 2005;51(4):287-93. doi: 10.1016/j.jinf.2004.10.003.
- 551 46. Gonçalves G, Cutts FT, Hills M, Rebelo-Andrade H, Trigo FA, Barros H. Transplacental  
552 transfer of measles and total IgG. *Epidemiol Infect* 1999;122(2):273-9. doi:  
553 10.1017/s0950268899002046.
- 554 47. Heininger U, Riffelmann M, Leineweber B, Wirsing von Koenig CH. Maternally derived  
555 antibodies against Bordetella pertussis antigens pertussis toxin and filamentous hemagglutinin  
556 in preterm and full term newborns. *Pediatr Infect Dis J* 2009;28(5):443-5. doi:  
557 10.1097/INF.0b013e318193ead7.
- 558 48. Munoz FM, Bond NH, Maccato M, Pinell P, Hammill HA, Swamy GK, et al. Safety and  
559 immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during  
560 pregnancy in mothers and infants: a randomized clinical trial. *JAMA* 2014;7;311(17):1760-9.  
561 doi: 10.1001/jama.2014.3633.
- 562 49. Korber B, Fischer W, Gnanakaran S, Yoon H, Theiler J, Abfalterer W et al. Tracking Changes  
563 in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.  
564 *Cell*. 2020;182(4):812-827.e19. doi: 10.1016/j.cell.2020.06.043
- 565 50. Bian L, Gao F, Zhang J, He Q, Mao Q, Xu M et al. Effects of SARS-CoV-2 variants on  
566 vaccine efficacy and response strategies. *Expert Review of Vaccines*. 2021;:1-9. doi:  
567 10.1080/14760584.2021.1903879
- 568 51. Gómez C, Perdiguero B, Esteban M. Emerging SARS-CoV-2 Variants and Impact in Global  
569 Vaccination Programs against SARS-CoV-2/COVID-19. *Vaccines*. 2021;9(3):243. doi:  
570 10.3390/vaccines9030243
- 571 52. Boehm E, Kronig I, Neher R, Eckerle I, Vetter P, Kaiser L. Novel SARS-CoV-2 variants: the  
572 pandemics within the pandemic. *Clinical Microbiology and Infection*. 2021. doi:  
573 10.1016/j.cmi.2021.05.022
- 574 53. Hoffmann M, Arora P, Groß R, Seidel A, Hörnich B, Hahn A et al. SARS-CoV-2 variants  
575 B.1.351 and P.1 escape from neutralizing antibodies. *Cell*. 2021;184(9):2384-2393.e12. doi:  
576 10.1016/j.cell.2021.03.036. doi: 10.1016/j.cell.2021.03.036
- 577 54. Starr T, Greaney A, Dingens A, Bloom J. Complete map of SARS-CoV-2 RBD mutations that  
578 escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. *Cell Reports*  
579 *Medicine*. 2021;2(4):100255. doi: 10.1016/j.xcrm.2021.100255
- 580 55. Wang P, Nair M, Liu L, Iketani S, Luo Y, Guo Y et al. Antibody Resistance of SARS-CoV-2  
581 Variants B.1.351 and B.1.1.7. 2021. doi: 10.1101/2021.01.25.428137

- 582 56. Torjesen I. Covid-19: Delta variant is now UK's most dominant strain and spreading through  
583 schools. *BMJ* 2021;373:n1445. doi:10.1136/bmj.n144. doi: 10.1136/bmj.n144
- 584 57. Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S et al. Effectiveness of  
585 COVID-19 vaccines against the B.1.617.2 variant. 2021. doi:  
586 <https://doi.org/10.1101/2021.05.22.21257658>
- 587 58. Ayouni I, Maatoug J, Dhouib W, Zammit N, Fredj S, Ghammam R et al. Effective public  
588 health measures to mitigate the spread of COVID-19: a systematic review. *BMC Public Health*.  
589 2021;21(1). doi: 10.1186/s12889-021-11111-1